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Abstract
Background and Objectives—For patients with cutaneous melanoma, primary tumors located 
in the head and neck is associated with poor outcomes. The reason for this difference and whether 
it is applicable to all locations within the head and neck remains unclear. We hypothesized that 
scalp melanoma is uniquely distinguished from other anatomic sites and is independently 
responsible for the poor prognosis of head and neck melanoma.
Methods—Query and analysis of a prospectively maintained melanoma database of all patients 
treated for primary cutaneous melanoma from 1971 – 2010.
Results—Of 11,384 patients identified, 7% (n=799) of lesions originated on the scalp. Scalp 
primaries were more often found in males and were associated with increased Breslow thickness 
and were more frequently ulcerated compared to all other anatomic sites (p=0.0001). On 
multivariate analysis, scalp location was an independent predictor of worse melanoma-specific 
(HR 1.75; CI 1.50–2.04; p<0.0001) and overall survival (HR 1.62; CI 1.41–1.86: p<0.0001).
Conclusions—This, the largest series examining scalp melanoma, confirms that scalp location is 
independently responsible for the negative prognosis associated with head and neck melanoma. 
Although the pathophysiology of this difference remains to be determined, these data argue for 
more rigorous surveillance of this anatomic location.
Keywords
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Introduction
Despite heightened public awareness and improvement in early detection through screening 
programs, cutaneous melanoma continues to represent one of several cancers with increasing 
incidence over the last several decades.[1] In particular, melanoma arising from the head and 
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neck region as a subgroup is being diagnosed with increased frequency.[2] Primary 
cutaneous melanoma of the head and neck consists of lesions arising on the scalp, face, ears, 
and neck, each occurring with distinct individual frequencies.[3] As a group, head and neck 
melanoma has long been associated with a worse overall prognosis compared to cutaneous 
melanoma arising from all other anatomic sites.[4] Whether these differences in long term 
outcomes may be attributed to unique anatomic, biologic or environmental factors remains 
unclear.
Melanoma arising on the scalp, as a subset of head and neck melanoma, has in the past been 
recognized as a “high-risk” anatomic location.[5–7] Large population based studies using 
the Surveillance, Epidemiology and End Results (SEER) database have suggested that scalp 
location may be an independent factor contributing to negative outcomes, in particular worse 
melanoma-specific and overall survival.[8, 9] Unfortunately, these studies have been 
constrained by the fact that scalp and neck melanoma are a combined category in the SEER 
database, so delineating the true impact of scalp location alone was not possible. In smaller 
series, examining the relative impact of individual sites of the head and neck generated 
conflicting results.[10, 11]
Therefore, to our knowledge, the clinical implication of scalp location on head and neck 
melanoma has not been adequately defined. We hypothesized that the scalp is associated 
with an outcome profile that distinguishes it from all other anatomic sites and is responsible 
for the generally poor prognosis attributed to melanoma of the head and neck.
Methods
We queried our prospectively maintained database from 1971 through 2010 for all patients 
diagnosed with cutaneous melanoma and having a known primary site. In order to avoid 
referral bias favoring recurrent cases as well as the effect of treatment delay due to referral 
time, analysis was limited to patients who were treated at our institution within 4 months of 
their initial diagnosis. Patients with more than one primary melanoma were excluded from 
analysis. Anatomic sites of the primary cutaneous melanoma were classified into the 
following subgroups: scalp, face/neck/ear, trunk and extremity.
Treatment consisted of wide local excision with excision margins determined by 
recommendations current during the treatment era as well as sentinel lymph node biopsy 
when indicated based on histopathological findings of the initial biopsy specimen. Clinical 
follow up consisted of complete dermatologic and physical examination every 3 months 
during the first 2 years and every 4–6 months for the next 3 years and then annually 
thereafter. Routine blood work including complete blood count, comprehensive metabolic 
panel and lactate dehydrogenase as well as radiographic studies were obtained annually 
when indicated based on pathologic stage.
Clinical factors such as age and gender as well as histopathological features including 
Breslow thickness, presence of ulceration, number of positive lymph nodes when examined, 
and overall stage based on the American Joint Committee on Cancer Staging Manual[12] 
were compared between anatomic sites of the primary cutaneous melanoma using chi-square 
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test. Melanoma-specific (MSS) and overall survival (OS) by primary site were analyzed and 
compared using Kaplan-Meier method and compared using the log-rank test. In order to 
account for survival differences based on stage, stage for stage survival analysis was 
performed. In order to identify significant independent predictors of 5-year melanoma-
specific (MSS) and overall survival (OS), multivariable analysis using Cox proportional-
hazards model was performed using a step-wise selection procedure to select the factors 
included in the final model.
Results
A total of 11,384 patients with a known primary melanoma were treated at our institution 
between January 1, 1971 and December 31, 2010. Of those 7% (n=799) originated on the 
scalp. The remainder of head and neck melanomas (face/neck/ear) consisted of 11% 
(n=1,241) of all melanomas treated at our center during the study period (Table 1). Males 
made up the majority (58%) of cases of melanoma and male gender was more common 
among all anatomic sites except extremity melanoma, which was more common among 
females. The proportion of males presenting with scalp lesions were significantly greater 
than any other anatomic site (80%, p=0.0001). Patients with trunk melanoma were 
significantly younger at the time of diagnosis compared to all other anatomic sites 
(p<0.0001). On average, lesions of the scalp were thicker at presentation (2.6 mm) compared 
to melanomas on the remainder of the head and neck (1.7 mm) (p<0.0001). In addition, 
presence of ulceration was less frequently identified in non-scalp head and neck locations 
compared to lesions of the scalp (10% vs. 16%, p=0.0001) (Table 2). Tumor-positive lymph 
nodes were more commonly associated with scalp primaries (20%) than any other anatomic 
site (p=0.0001).
On univariate analysis, scalp location was associated with significantly reduced 5-year OS 
for all stages compared to all other anatomic sites (p<0.0001) (Figure 1a). When stage IV 
patients were excluded from analysis a statistically significant worse overall survival 
remained (p<0.0001) among scalp melanoma patients compared to the other groups (Figure 
1b). This effect persisted when anatomic site was compared stage for stage among stage I 
and II patients (Figure 1c) as well as stage III patients alone (Figure 1d).
Multivariable analysis was performed to identify independent predictors of reduced 5-year 
MSS and OS. The analysis included common prognostic variables such as age, sex, primary 
anatomic site, tumor thickness categorized by T-stage, presence of ulceration, and lymph 
node status. Analysis revealed that scalp location was independently associated with worse 
MSS (HR 1.75; CI 1.50–2.04; p<0.0001) and OS (HR 1.62; CI 1.41–1.86; p<0.0001) 
compared to all other anatomic sites (Table 3). Other head and neck primary tumor locations 
were not significantly associated with outcomes worse than extremity, the reference site. 
Age, sex, T stage, ulceration and nodal status were also significant.
Given the significantly worse MSS and OS associated with primary lesions of the scalp, we 
elected to perform additional analysis to determine if this negative affect on survival could 
be attributed to higher rates of developing metastatic disease. As demonstrated in Figure 2, 
scalp location had worse distant disease-free survival compared to all other anatomic sites. 
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Furthermore, on multivariable analysis, scalp location was independently associated with a 
2-fold worse distant disease-free survival (HR 2.06; CI 1.79–2.38; p<0.0001).
Discussion
The role of primary anatomic site as a prognostic indicator in cutaneous melanoma has been 
debated for decades.[5–7] Although several studies have attempted to elucidate the impact of 
anatomic site in the context of head and neck melanoma in the past, the relative impact of 
scalp location alone has remained unclear. Urist et al. published an early series on head and 
neck melanoma in 534 clinically stage I patients and noted that patients with scalp and neck 
melanoma had a worse prognosis than tumors located on the face or ear[4]. A more recent 
study by Leong et al. examined the impact of sentinel node status and other common 
prognostic factors on outcomes in a cohort of 629 patients with head and neck melanoma 
who underwent sentinel lymph node biopsy. This study reaffirmed that tumor site was 
indeed an independent predictor of mortality with scalp location being associated with the 
highest rate of recurrence and a more than 3-fold greater mortality than tumors of the face.
[13] In the Sunbelt Melanoma Trial, among patients who underwent sentinel lymph node 
biopsy for melanomas > 1.0 mm in thickness and clinically negative nodal disease, scalp and 
non-scalp head and neck melanoma had differing clinical and histopathological features that 
affected long term outcomes. Of their 109 scalp melanoma patients, sentinel lymph node 
status was the strongest predictor of overall survival while in non-scalp melanoma patients, 
Breslow thickness and presence of ulceration were the primary predictors associated with 
reduced survival.[14] Unfortunately, while each of these series is informative, conclusions 
drawn are inherently limited by the small populations of patients examined. In order to 
address, this limitation, large population-based database analyses have been performed and 
have produced similar results. Using the SEER database, scalp and neck melanoma were 
associated with significantly decreased MSS and OS compared with other areas of the head 
and neck.[8, 9] The most recent of these studies by Tseng et al. featured a robust number of 
patients (n=27,097) of which 34% presented with melanoma of the scalp or neck. 
Unfortunately, SEER does not differentiate between scalp and neck melanoma, instead 
combining both of these anatomic sites into one category for analysis. Therefore, it is 
impossible to assess the true impact of scalp location alone.
In the current study, we sought to compare a pure population of primary cutaneous scalp 
melanoma patients to all other anatomic sites at a single institution using a large 
prospectively maintained melanoma database. We found that non-scalp head and neck 
melanoma had similar 5-year MSS and OS compared to melanoma of the trunk and 
extremities. Conversely, scalp melanoma was associated with significantly worse 5-year 
MSS and OS. Even after excluding stage IV patients, scalp primary site, thicker Breslow, 
lymph node positivity, presence of ulceration, older age and male gender were all found to 
be associated with significantly worse overall and melanoma-specific survival. Taken 
together these findings suggest that scalp melanoma represents a distinct entity and is 
probably responsible for the generally poor prognosis associated with head and neck 
melanoma. In addition, scalp melanoma appears to behave in a more aggressive fashion 
compared to melanoma originating from other anatomic sites.
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Several theories have been proposed to explain why scalp melanoma may be associated with 
worse outcomes compared to melanoma originating from other anatomic sites. The 
lymphatic drainage pattern of the scalp is complex and can often be variable and 
unpredictable.[15–17] To highlight this fact, it has previously been reported that the rate of 
false-negative sentinel lymph node biopsy in head and neck melanoma may be as high as 
32%.[18] Therefore, anatomic variations in lymphatic drainage patterns of the head and neck 
may predispose to greater risk of distant site recurrence. This was demonstrated in the 
current study, as scalp location was independently associated with worse distant disease-free 
survival compared to all other anatomic sites. In addition, it has been hypothesized that 
given anatomic constraints of the scalp, patients may undergo inadequate excision 
predisposing to higher rates of local recurrence.[19] Finally, as shown in this study, 
melanoma of the scalp typically presents at more advanced stages with thicker lesions, more 
frequently are ulcerated and more commonly are associated with nodal involvement. Taken 
together, these findings may suggest that scalp lesions go unrecognized due to their location 
or possibly are associated with longer delay times between time of patient recognition and 
initial presentation to a health care provider.
Recently, mutations in the N-ras oncogene have been recognized as a common genetic 
mutation occurring in cutaneous melanoma with an incidence as high as 18%.[20] This 
mutation has been associated with specific histologic subtypes of melanoma as well as 
distinctive tumor locations, predominately being found in nodular melanoma arising in the 
setting of areas of chronic sun-damaged skin secondary to exposure to ultraviolet radiation.
[20, 21] Head and neck melanoma, given their anatomic location and propensity for sun 
exposure, appears to be particularly susceptible to N-ras mutations. Jiveskog et al. compared 
frequencies of N-ras mutations between sun-exposed areas of the head and neck to 
unexposed regions of the body and found N-ras to be mutated in 32% of head and neck 
melanoma specimens, but only 7% of melanomas developing in unexposed sites.[22] N-ras 
mutations have also been shown to be associated with thicker lesions and have higher rates 
of mitotic activity. Furthermore, N-ras mutation appears to be an independent adverse 
prognostic factor associated with decreased MSS (HR 2.96, p=0.04).[23] Therefore, a 
complex combination of anatomic, biologic and environmental factors may be contributing 
to the aggressive nature and pathogenesis of scalp melanoma.
There are several limitations to the current study. Given the duration of the studied time 
period, significant variations in standard staging procedures undoubtedly occurred, which 
may make the study population somewhat heterogeneous. In addition, there may exist a 
component of referral bias among the cohort of patients studied given we are a tertiary 
melanoma-referral center. However, referral bias would be unlikely to selectively affect 
scalp melanomas, and the extent of this bias should be limited by our exclusion of patients 
not seen at our center within 4 months of their initial diagnosis or with multiple primary 
melanomas. Finally, our multivariable analysis included T and N stage independently rather 
than AJCC staging because of the issue of collinearity in multivariable analysis, since T and 
N stage are factors determining AJCC stage. Nonetheless, analysis was repeated using AJCC 
stage and similar results were obtained.
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In summary, scalp melanoma appears to present at later stage and behave more aggressively 
than melanoma from all other anatomic sites. Anatomic, biologic and environmental factors 
may contribute to the pathogenesis of scalp melanoma. Further studies to elucidate the 
unique characteristics of scalp melanoma are warranted. Clinically, decisions concerning 
indication for sentinel lymph node biopsy in thin melanomas of the scalp should be made in 
light of these findings. In addition, closer follow-up may be warranted among these patients 
due to increased rates of recurrence. Non-scalp head and neck melanoma may not carry as 
negative a prognosis as previously thought. These findings support increased attention to the 
scalp as a component of skin surveillance in an effort to improve early detection and 
improve outcomes.
Conclusion
We report the largest series of scalp melanoma to date. Scalp melanoma is associated with 
reduced melanoma-specific and overall survival compared to non-scalp head and neck, trunk 
and extremity melanoma. Thus, scalp melanoma alone may be responsible for the overall 
poor long term outcomes of head and neck melanoma as a whole. Additional studies are 
warranted to ascertain unique biologic, anatomic or environmental factors contributing to the 
pathogenesis of scalp melanoma.
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Comparison of 5-Year Overall Survival for Cutaneous Melanoma Stratified by Anatomic 
Site for A) All Stages, B) with Stage IV Excluded, C) Stage I and II Only and D) Stage III 
Only
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Comparison of 5-year Distant Disease-Free Survival Stratified by Anatomic Site of Primary 
Cutaneous Melanoma, All Stages
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Table 2
Comparison of Demographics and Histopathological Characteristics for Patients with Scalp vs Non-Scalp 
Head and Neck Melanoma
Face/Neck/Ear Scalp Total
P-value
Variable n=1241 n=799 n=2040
Gender
  Male 860 (69) 638 (80) 1498 (73) <0.0001
  Female 381 (31) 161 (20) 542 (27)
Age
  Mean +/− SD 56 +/− 16.8 54 +/− 18.0 <0.0001
Breslow
  Mean +/− SD 1.7 +/− 1.6 2.6 +/− 3.2 <0.0001
Ulceration
  Absent 787 (63) 467 (58) 1254 (62) 0.0004
  Present 122 (10) 125 (16) 247 (12)
  Unknown 332 (27) 207 (26) 539 (26)
Nodal stage
  N0 406 (33) 263 (33) 669 (33) <0.0001
  N1 57 (5) 75 (9) 132 (6)
  N2 36 (3) 49 (6) 85 (4)
  N3 13 (1) 42 (5) 55 (3)
  Unknown 729 (59) 370 (46) 1099 (54)
AJCC Stage
  I/II 798 (64) 416 (52) 1214 (60) <0.0001
  III 216 (17) 241 (30) 457 (22)
  IV 209 (17) 132 (17) 341 (17)
  Unknown 18 (2) 10 (1) 28 (1)
AJCC = American Joint Committee on Cancer
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Table 3
Cox Proportional-Hazards Model of 5-Year Melanoma-Specific, Overall and Distant-Disease Free Survival
Multivariable 5-Year MSS Multivariable 5-Year OS Multivariable 5-Year DDFS
HR (95% CI), P-value HR (95% CI), P-value HR (95% CI), P-value
Variable
Male Sex 1.27 (1.16–1.38), <.0001 1.26 (1.16–1.37), <0.0001 1.25 (1.14–1.36), <.0001
Age (continuous) 1.01 (1.01–1.01), <.0001 1.02 (1.02–1.02), <0.0001 1.00 (1.00–1.01), 0.0001
Primary Site
  Extremity (ref) ** ** **
  Scalp 1.75 (1.50–2.04), <.0001 1.62 (1.41–1.86), <.0001 2.06 (1.79–2.38), <.0001
  Face/Neck/Ear 1.15 (0.98–1.34), 0.0930 1.13 (0.99–1.30), 0.0770 1.37 (1.19–1.59), <.0001
  Trunk 1.36 (1.22–1.51), <.0001 1.27 (1.16–1.39), <.0001 1.37 (1.24–1.52), <.0001
T stage
  T1: 0.01–1.00 (ref) ** ** **
  T2: 1.01–2.00 2.18 (1.87–2.55), <.0001 1.89 (1.65–2.15), <.0001 2.30 (2.00–2.65), <.0001
  T3: 2.01–4.00 3.93 (3.37–4.58), <.0001 3.11 (2.73–3.55), <.0001 3.68 (3.19–4.25), <.0001
  T4: >4.00 5.24 (4.43–6.20), <.0001 4.13 (3.57–4.78), <.0001 5.03 (4.29–5.9), <.0001
  T: Unknown 3.23 (2.78–3.75), <.0001 2.41 (2.12–2.74), <.0001 2.94 (2.56–3.38), <.0001
Ulceration
  Absent (ref) ** ** **
  Present 1.95 (1.74–2.18), <.0001 1.79 (1.62–1.98), <.0001 1.92 (1.72–2.14), <.0001
  Unknown 1.98 (1.80–2.19), <.0001 1.88 (1.72–2.05), <.0001 2.18 (1.98–2.39), <.0001
Lymph Node Status
  Negative (ref) ** ** **
  Positive 3.01 (2.68–3.37), <.0001 2.77 (2.50–3.07), <.0001 2.58 (2.31–2.88), <.0001
  Unknown 1.32 (1.18–1.46), <.0001 1.31 (1.19–1.44), <.0001 1.28 (1.15–1.41), <.0001
J Surg Oncol. Author manuscript; available in PMC 2018 September 01.
